Introduction
Colorectal cancer (CRC) is one of the most prevalent cancers in the world. It is the third most common cancer and the second most common cause of cancer-related mortality worldwide (1) . The mortality rate has changed little over the last 30 years despite advances that have been made in understanding the pathogenesis of this cancer at the molecular level.
Among patients who undergo curative surgery, some patients develop local recurrence or distant metastases leading to shorter survival (2) . The TNM classification proposed by the International Union Against Cancer remains the indicator of prognosis and provides the basis for therapeutic decision making (3) . However, the current TNM classification system is limited in that it cannot predict prognosis for individual patients. To improve the prognosis of CRC, there is a crucial need to explore cancer-related genes that can serve as predictive biomarkers for individualization of therapy (4) .
Microarray analysis allows the exploration of several thousands of cancer-related or cancer-specific genes (5) . The potential of expression microarray analysis can provide significant insight into biological differences between patients with good and poor prognoses, and can be used as a screening tool to find individual molecules for individualization of therapy.
Inactivation of the apoptotic pathway is an important mechanism that leads to tumor progression and tolerance to antitumor drugs (8) . Thus, clarifying the mechanisms of apoptotic dysfunction may help provide new approaches for CRC treatment. In this study, we identified osteoprotegerin (OPG; TNFRSF11B) as a gene related to distant metastases in CRC patients.
OPG helps cancer cells survive by providing resistance to apoptosis induced by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (9) .OPG isa secreted member of the tumor necrosis factor receptor superfamily that acts as a decoy receptor binding to TRAIL and neutralizing its apoptotic function (10) . This is the first study that revealed the clinicopathologic significanceof OPG expression by using clinical tissue samples from patients with CRC. 
Statistical analysis
Statistical analyses of microarray data were normalized using the robust multi-array average method with R 2.6.2 statistical software together with the BioConductor package(R Foundation for Statistical Computing, Vienna, Austria), as described previously (11, 12) . Differences between two groups were estimated using the Mann-Whitney U test for 104 LCM patients and for homogenized samples of whole tumor and tumor adjacent tissues.
Research. Differences between groups were estimated using the Mann-Whitney U test and the χ 2 test. Correlation was estimated using the Spearman's rank correlation coefficient. Survival curves were estimated by the Kaplan-Meier method, and comparisons between curves were made by the log-rank test.
Prognostic factors were examined by univariate and multivariate analyses (Cox proportional hazards model).A probability level of 0.05 was used for statistical significance.
Results

Microarray analysis
In the microarray analysis, six genes (COL9A3, SERPINB5, HOXB8, OPG, STXBP1, and TWSC) were identified that fulfilled the specified criteria.
Three genes were associated with human cancer: SERPINB5, HOXB8, and OPG. Among these genes, OPGwas suspected to play a role in cell survival through its antiapoptotic action. The high expression of OPG has been shown to be associated with worse prognosis in several solid cancers (13) (14) (15) (16) 
Expression of OPG mRNA in cancer tissues
Quantitative RT-PCR analyses of 77 patients with CRC showed that OPG mRNA expression levels were significantly higher in tumors than in corresponding normal tissues (p<0.001; Fig. 1A ). The expression of OPG mRNA was significantly higher in tumors in the metastatic group than in the non-metastatic group (p = 0.035; Fig. 1B ). other significant differences in clinicalpathologic features between the lowand high-expression groups among these 226 patients. The relapse-free survival rate (RFS) was significantly lower (P = 0.001) in patients with high OPG protein expression than in those with low OPG expression (Fig. 3B) .
Expression of OPG protein in cancer tissues
Univariate analysis showed that the following factors were significantly associated with worse RFS: gender, histology, tumor depth, lymphatic invasion, venous invasion, lymph node metastasis, CEA level, and high OPG expression (Table 3) .Multivariate analysis using the Cox proportional hazards model indicated that histology, tumor depth, lymph node metastasis, CEA level, and high OPG expression were associated with worse RFS.
Discussion
OPG was initially identified as a protein that regulates bone resorption (17) (18) (19) (20) . It is a member of the tumor necrosis factor receptor superfamily, but it differs from other members due to a lack of a transmembrane domain. Because of the lack of this domain, OPG acts as a decoy-receptor, binding to TRAIL and neutralizing its function (9, 10) .
TRAIL is the principle mediator of the extrinsic-apoptotic pathway, which 
has tumor-killing activity, and is being investigated for its therapeutic potential to induce tumor cell death (21) .TRAIL triggers apoptosis by binding to death receptors 4 and 5 on the surface of cells (22) . OPG produced by tumor cells binds to TRAIL and prevents the activation of death receptors 4 and 5 (17) .Thus,OPG is thought to protect against the antiapoptotic action in OPG-expressing cells by overcoming the mechanism induced by TRAIL.Indeed, some studies suggest that OPG production and release into the serum of patients is likely to exert an antiapoptotic effect on tumor cells during the invasion and metastasis process (23) (24) (25) . In addition to the roles of OPG in tumor cell survival described above, OPG has been reported to be a positive regulator of tumor microvessel formation (26, 27) . If OPG does have a significant function in the vasculature, this may have implications for tumor angiogenesis, a key process in cancer development and metastasis.
OPG production is suggested to be part of a tumor cell survival strategy, and a number of different tumor cells, such as prostate, breast, and gastric cancer cells, have been found to produce OPG (13, 15, 16) . However, the OPG expression status in CRC has only been analyzed in the cell line and serum (28, 29) . It is reported that serum OPG levels were increased in patients with Despite curative surgery for localized disease, approximately 40% of CRC patients will eventually relapse (32) . Recently, some adjuvant chemotherapies for patients with CRC have been shown to be associated with improved cure rates after surgery (33) . However, even though these chemotherapies have been shown to be effective, they are costly and are associated with severe adverse effects. Therefore, there exists a need to identify patients who would benefit from adjuvant chemotherapy prior to treatment; molecular markers may give us important insight into this challenge (34, 35) , as these markers can be taken into account when selecting the appropriate chemotherapy. Our study suggests that high expression of OPG protein is a novel marker for recurrence after curative surgery for CRC. OPG might be a useful biomarker to decide whether to use adjuvant chemotherapy in patients with CRC after curative surgery.
In the last decade, the development of novel therapies that target critical biologic pathways has greatly expanded treatment options for patients with CRC and has shown substantial improvement in survival (36) . 
